Interpace Diagnostics Group Inc (NASDAQ:IDXG)

Interpace Diagnostics Group, Inc. engages in the development and commercialization of molecular diagnostic test. It focuses on early detection high potential progresses to cancer. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment; ThyGenX which assesses thyroid nodules for risk of malignancy; and ThyraMIR, which assesses thyroid nodules for risk of malignancy utilizing a proprietary gene expression assay. The company was founded by John P. Dugan in 1987 and is headquartered in Parsippany, NJ.